Даваа–Баасан 08:30–20:00 · Бямба 09:00–16:00
library@mnums.edu.mn
/

Namdag, Bira

Loading...
Thumbnail Image
Товч нэр
Namdag, Bira
Бүтэн нэр
Namdag Bira
Латин нэр
Namdag Bira
Албан тушаал
Судлаач
Харьяалал
ORCID

Settings

Now showing 1 - 2 of 2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Clarithromycin Resistance in Helicobacter Pylori
    (Mongolian National University of Medical Sciences, 2016-06-25)
    Mandkhai Bolor-Erdene
    ;
    Bira Namdag
    ;
    Sarantuya Jav
    Objectives: Eradication rates of Helicobacter pylori with standard triple therapy are disappointing in studies from several countries. The main reason for failure was found to be bacterial resistance to one of the most commonly used antibiotics, clarithromycin. Our aim was to determine the prevalence of clarithromycin resistance among H. pylori strains isolated from Mongolians and the presence of associated mutations to these antibiotics. Methods: All urease-positive samples were cultured according to the standard microbiological procedures. H. pylori strains were grown under microaerophilic conditions on H. pyloriselective agar. H. pylori antibiotic sensitivity was examined using the E-test method. The GenoType HelicoDR, which employs reverse hybridization, was used to confirm the presence of H. pylori, determine its susceptibility to antimicrobials and detect mutations conferring resistance to clarithromycin. Results: Ourfindings show that 51 (53.7%) ofH. pyloristrains were resistantto clarithromycin. Mutations were observed in 32 (53.7%) strains with A2147G being the most prevalent, A2146G being the least prevalent and A2146C point mutation being undetected. Conclusion: In the present study, H. pylori strains with moderate-level clarithromycin resistance are more frequently found and clarithromycin is associated with point mutation A2147G in Mongolians.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Initial Trials With Susceptibility-Based and Empiric Anti-H. pylori Therapies in Mongolia
    (Frontiers Media SA, 2019)
    Byambajav, Tsogt-Ochir
    ;
    Bira, Namdag
    ;
    Choijamts, Gotov
    ;
    Davaadorj, Duger
    ;
    Gantuya, Boldbaatar
    Background: Mongolia has a high prevalence of Helicobacter pylori infection and gastric cancer. We conducted a prospective, randomized, single-blind study to evaluate the efficacy of common regimens in Mongolia and to obtain specimens for susceptibility testing. Methods: Empiric treatments: 270 patients with confirmed H. pylori infection were randomized to receive 10 days clarithromycin-triple therapy (Clari-TT) (n = 90), modified bismuth quadruple therapy (M-BQT) (n = 90), or sequential therapy (ST) (n = 90). A second group of 46 patients received susceptibility-based Clari-TT. H. pylori was cultured from 131 patients and susceptibility testing was performed. H. pylori eradication was confirmed by stool antigen 4 weeks after the therapy. Results: Intention-to-treat (ITT) analysis cure rates were 71.1% (95% CI = 61.7-80.5%) for Clari-TT, 87.8% (95% CI = 81-94.6%) for M-BQT, 67.8% (95% CI = 58.1-77.5%) for ST vs. 89.1% (95% CI = 86-98.2%) for susceptibility-based Clari-TT. Per-protocol (PP) analysis results for these therapies were 72.7% (63.4-82%), 89.8% (83.5-96.1%), 68.5% (58.8-78.2%), and 97.6% (89.5-99.8%), respectively. Among 131 cultured H. pylori, resistance rates to amoxicillin, clarithromycin, and metronidazole were 8.4, 37.4, and 74%, respectively. Conclusion: In Mongolia, the prevalence of H. pylori resistance is high requiring bismuth quadruple therapy or susceptibility-based therapy to obtain acceptable cure rates.
    Scopus© Citations 12